We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bespak | LSE:BPK | London | Ordinary Share | GB0000946276 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 667.00 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 667.00 | GBX |
Bespak (BPK) Share Charts1 Year Bespak Chart |
|
1 Month Bespak Chart |
Intraday Bespak Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 20/6/2007 | 20:59 | Director buying at Bespak..have we reached the bottom? | 127 |
| 28/2/2002 | 11:25 | short sale | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 20/4/2007 08:08 by playtime99 Anyone care to comment on the recent price drop at BPK, is it solely due the reported slow take up of Exubera, or is the recently announced acquisition partly responsible ... are they overpaying?Thanks for any contributions. |
Posted at 19/1/2007 19:54 by tuning peg This has always been a solid if unexciting business with good management. The CFC inhaler market decline will hopefully be offset by non CFC inhaler sales plus Exubera (if we share the company's optimism). More interestingly in my view is the sea change in the company's ambitions e.g. doubling profits in five years and hinting strongly that they will achieve this through acquisitions rather than relying on organic growth. At least the management have put their necks on the line and we must salute them for this.My real concerns are that it has always been a cash rich company. With the acquisistion of King the war chest has gone and the company is now in debt. Further acquisitions will ramp up debt so the pressure is on to make some quality acquisitions. Additionally we need to be mindful that King has increased the company's dollar exposure and in the current £/$ rate environment this could be a drag on profitability. The flip side of course is that future $ acquisitions become much cheaper and I suspect that given Throdahl is American with prior experience of the US pharma / medical devices market he centre his focus in this area For what it is worth I am in pretty big on BPK and I am fully intending to hold and will look to buy more on any weakness but given the rises over the last 2 days it might be lucky if I get back in sub £7 at this rate. |
Posted at 11/9/2006 15:24 by tiltonboy c2i,I've taken profits on BPK, selling the last lot at 672p, just over a week ago. Whilst I think there might be more in it, I am happy with the % gain, in a relatively short space of time. There are a couple of cautionary comments in the statement, so better to bag the profit. tiltonboy |
Posted at 11/9/2006 15:08 by contrarian2investor I wonder if today's new rise in down to more institutions coming on board or is has BPK been tipped somewhere? Any news fellow holders?Thanking you in anticipation of your reply c21 |
Posted at 31/8/2006 16:36 by contrarian2investor tiltonboy,sorry that I didn't reply earlier. My reasons for my earlier speculation is thus: Bespak is the leader in the UK of inhaleable products, Glaxo have already made a massive investment in BPK's product line. They (Glaxo) need additional revenues, so what better way than taking this nice little cash cow in-house. If you look at recent purchases by Pharma companies they have mainly been bios. So BPK is in an interesting position. Today we have had another nice rise to a five year high and Barclays have been buying up their holdings again over the past 2 months. So BPK should breach £7 before 2007. Then the sales will really kick in during 2007 and others will start touting them, so watch this space. All in my humble opinion. DYOR. By the way Tiltonboy do happen to hold BPK shares? Your's with integrity, C2I |
Posted at 07/6/2006 19:14 by tiltonboy c2i,Bespak make consummables not drugs, so I can't see Glaxo or a pharma buying them. If you want an interesting little bio that could get taken over have a look at HML. They have an application for a multi billion $ market, and are finalising the terms of a licence to a US pharma. If you look at what price AZN paid PTI for one of their products, and what price Novartis were willing to pay for NTP who currently have no turnover, then HML could be an interesting little bet. As always DYOR. tiltonboy |
Posted at 07/6/2006 17:33 by contrarian2investor Well I'm not going anywhere until Glaxo make a move. In light of the fact that the big pharma's appear to be buying the small/medium size biotech for future growth. Eventually BPK will be snapped up. In the meantime it has been a relatively safe port in the storm. c21 |
Posted at 19/4/2006 08:07 by felix99 Hmmm . NICE have rejected Exubera for the NHS last night. Wonder if it will have an effect on BPK . They make the inhalers and have a royalty deal with Pfizer. Must be a potnetial £100m sale down the swanny for a bit. They earn 15% royalty I beleive. Anyone know if that is on top of production costs or essentially an all inclusive price? |
Posted at 02/2/2006 11:48 by ved I read a comment by Bridgewell Securities (reported by InvestorEase) that they suggest selling the stock as it stands at 30% premium to rivals and it will take some time for benefit from Exubera to show. This may be reason for the drop in price IMO. Any comments from other holders of this stock will be welcome. |
Posted at 19/1/2006 22:01 by tiltonboy Ved,If you are online tomorrow morning I will tell you who is on the offer and in what size. The problems are being caused by the decision of the LSE to move a large number of stocks to SETS MM. The marketmakers are no longer willing to make prices in any size, and the spreads have widened markedly. If you go on the board yourself, somebody puts an order in inside your price in just a few shares. I had orders to buy the stock when the shares were around 485p, but I had enormous difficulty in dealing, on what I considered to be a sensible spread. tiltonboy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
